Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Negative Regulation of Immune Cell Destruction	NCIT_C40728	[Any process that decreases the frequency, rate or extent of apoptosis in leukocytes.]
Negative Regulation of Lymphocyte Apoptotic Process	NCIT_C40729	[Any process that decreases the frequency, rate or extent of apoptosis in B cells, T cells or natural killer cells.]
Percent Predicted Forced Expiratory Volume in 1 Second	NCIT_C112376	[Forced expiratory volume in one second as a proportion of the predicted normal value. (CDISC)]
Extracranial Solid Neoplasm	NCIT_C151940	[A solid neoplasm involving any anatomic site other than the brain.]
Solid Neoplasm	NCIT_C9292	[A benign or malignant neoplasm arising from tissues that do not include fluid areas. Representative examples include epithelial neoplasms (e.g. lung carcinoma, prostate carcinoma, breast carcinoma, colon carcinoma), and neoplasms arising from the soft tissues and bones (e.g. leiomyosarcoma, liposarcoma, chondrosarcoma, osteosarcoma). Neoplasms originating from the blood or bone marrow (leukemias and myeloproliferative disorders) are not considered solid tumors.]
Percent Predicted Forced Expiratory Volume in 1 Second Divided by Forced Vital Capacity	NCIT_C112377	[The proportion of total forced vital capacity that is expelled during the first second of a forced exhalation as a proportion of the predicted normal value. (CDISC)]
Acyclic Nucleoside Phosphonate Prodrug ABI-1968	NCIT_C151941	[A prodrug of an acyclic nucleoside phosphonate, with potential anti-viral and antineoplastic activities. Upon administration, acyclic nucleoside phosphonate prodrug ABI-1968 is taken up by viral-infected cells and converted to its active metabolite. The metabolite is incorporated into DNA chains by DNA polymerases, which results in the termination of DNA synthesis, inhibits viral replication and induces apoptosis and inhibits the proliferation of susceptible virally-infected tumor cells.]
Antimetabolite	NCIT_C272	[An antineoplastic agent with a structural similarity to a natural substance that can replace that substance in a normal biochemical pathway and interfere with the normal metabolic processes of cells.]
Percent Predicted Forced Expiratory Volume in 6 Seconds	NCIT_C112378	[Forced expiratory volume in six seconds as a proportion of the predicted normal value. (CDISC)]
Therapeutic Liver Cancer Peptide Vaccine IMA970A	NCIT_C151942	[An off-the-shelf hepatocellular cancer (HCC) multi-peptide-based therapeutic vaccine composed of sixteen peptides derived from tumor-associated antigens (TAAs) expressed by hepatic tumor cells, of which seven are restricted to human leukocyte antigen (HLA)-A2 (HLA-A02), five to HLA-A24 and four to HLA class II, with potential immunomodulating and antineoplastic activities. Upon intradermal administration of the therapeutic liver cancer peptide vaccine IMA970A, the liver-specific peptides in the vaccine activate the immune system to exert both CD4+ T-helper and CD8+ cytotoxic T-lymphocyte (CTL)-mediated immune responses against liver cancer cells.]
Percent Predicted Forced Inspiratory Flow Maximum	NCIT_C112379	[Forced inspiratory flow for a portion of the FVC curve at the point where the maximum portion of FVC is already inhaled as a proportion of the predicted normal value. (CDISC)]
Bivalent BRD4 Inhibitor AZD5153	NCIT_C151943	[An orally bioavailable bivalent inhibitor of bromodomain-containing protein 4 (BRD4), with potential antineoplastic activity. Upon oral administration, the BRD4 inhibitor AZD5153 selectively binds to the acetylated lysine recognition motifs in two bromodomains in the BRD4 protein, thereby preventing the binding of BRD4 to acetylated lysines on histones. This disrupts chromatin remodeling and dysregulates expression of target genes, which leads to the downregulation of the expression of certain growth-promoting genes, induces apoptosis and inhibits the proliferation of BRD4-overexpressing tumor cells. BRD4, a member of the human bromodomain and extra-terminal (BET) family of proteins, is a transcriptional regulator that is overexpressed in certain tumor cells and plays an important role in cellular proliferation.]
Percent Change From Baseline in Sum of Volume	NCIT_C112372	[The most recently recorded sum of volumes minus the baseline sum of volumes divided by the baseline sum of volumes, multiplied by 100.]
Percent Change From Nadir in Sum of Diameter	NCIT_C112373	[The most recently recorded sum of diameters minus the lowest sum of diameters previously recorded divided by the lowest sum of diameters previously recorded, multiplied by 100.]
Percent Change From Nadir in Sum of Longest Diameter	NCIT_C112374	[The most recently recorded sum of longest diameters minus the lowest sum of longest diameters previously recorded divided by the lowest sum of longest diameters previously recorded, multiplied by 100.]
Percent Predicted Expiratory Reserve Volume	NCIT_C112375	[The maximum volume of air a subject can exhale from the lungs after a tidal exhalation as a proportion of the predicted normal value. (CDISC)]
RhoC Peptide Vaccine RV001V	NCIT_C151937	[A cancer vaccine composed of an immunogenic peptide derived from the Ras homolog family member C (RhoC; Rho-related GTP-binding protein RhoC) that is emulsified in the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, RhoC peptide vaccine RV001V may stimulate the host immune system to mount a humoral and cytotoxic T-lymphocyte (CTL) response against tumor cells expressing RhoC, which results in tumor cell lysis. RhoC, a tumor-associated antigen (TAA) that is overexpressed in a variety of tumor cell types, is associated with increased metastatic potential.]
Pelvic Mass	NCIT_C151938	[A benign or malignant tumor-like pathologic process involving the organs and structures in the pelvis.]
Fluorescence Imaging Agent IC2000	NCIT_C151939	[A fluorescent imaging agent that can potentially be used as a diagnostic imaging agent.]
Percent Change From Baseline in Sum of Diameter	NCIT_C112370	[The most recently recorded sum of diameters minus the baseline sum of diameters divided by the baseline sum of diameters, multiplied by 100.]